Drug Discovery: Decoding the mechanisms of allostery

A complex interplay between structure, conformational dynamics and pharmacology defines distant regulation of G protein-coupled receptors.
  1. Saif Khan
  2. Cornelius Gati  Is a corresponding author
  1. Bridge Institute, USC Michelson Center for Convergent Biosciences, Department of Biological Sciences, University of Southern California, United States

G protein-coupled receptors are transmembrane proteins that help to regulate a wide array of biological processes, which makes them important drug targets. However, different receptors often share a high similarity in their sequences, especially at their binding sites, which often results in challenges to develop drugs that target a specific receptor (Vuckovic et al., 2019; Singh and Karnik, 2021).

For example, the five members of a muscarinic acetylcholine receptor subfamily (M1-M5 mAChR) have essential roles in various physiological processes (Wess et al., 2007). In particular, M4 mAChR is of major therapeutic interest due to its involvement in regulating dopaminergic neurons involved in cognition, psychosis and addiction, while others, such as M1 mAChR, can be targeted to treat cognitive decline in Alzheimer’s disease (Wess et al., 2007). However, these receptors share highly similar binding sites, and drugs that target a particular mAChR receptor often inadvertently activate other receptors in the subfamily, thereby causing adverse side effects (Felder et al., 2018).

As an alternative to targeting the primary binding site on the receptor (also known as the orthosteric site) with a drug, it is sometimes possible to regulate a receptor by targeting a remote (or allosteric) site. Since there is much less similarity in the sequences of allosteric sites, this approach makes it possible to design highly selective drugs with reduced side effects.

Now, in eLife, David Thal, Arthur Christopoulus and Celine Valant (all at Monash University), Yinglong Miao (University of Kansas) and colleagues – including Ziva Vuckovic, Vi Pham and Jesse Mobbs (all at Monash) and Jinan Wang (Kansas) as joint first authors, along with colleagues in Japan, the United Kingdom and the United States – report on the molecular mechanisms that govern allostery in human M4 AchR (Vuckovic et al., 2023). The researchers used two ligands that targeted the orthosteric site (acetylcholine and iperoxo), and two positive modulators that targeted the allosteric site (VU154 and LY298). Both modulators have shown antipsychotic efficacy in preclinical rodent models, but these results have failed to translate into human studies (Suratman et al., 2011; Dupuis et al., 2010). Nevertheless, they remain useful tools for investigating allostery in G protein-coupled receptors (Bubser et al., 2014).

Vuckovic et al. used two types of biochemical assays to determine the pharmacological characteristics of the allosteric modulators. This revealed that both LY298 and VU154 display a phenomenon called ‘probe dependence’, meaning that they had a stronger effect when the orthosteric ligand was acetylcholine rather than iperoxo. They also showed that these effects were caused by an increase in the binding affinities of the orthosteric ligands, rather than by any modulation of signaling through the receptor (Figure 1A). Moreover, LY298 was the more potent modulator as it caused a 400-fold increase in binding affinity, compared with a modest 40-fold increase for VU154.

Allosteric regulation of G protein-coupled receptors.

(A) G protein-coupled receptors (GPCRs) are transmembrane proteins (bottom) that can be regulated by orthosteric ligands (such as acetylcholine or iperoxo) and positive allosteric modulators (PAMs). Vuckovic et al. studied a receptor called M4 AChR and found that two PAMs (VU154 or LY298; purple stars) bind more tightly when the orthosteric ligand is acetylcholine (green circle), and less tightly when it is iperoxo (blue circle); this is referred to as “probe dependance”. (B) This probe dependence can be explained by differences in the binding of acetylcholine and iperoxo at the orthosteric site, which is inside a ‘pocket’. This pocket contracts around iperoxo, which results in iperoxo and the allosteric ligand forming a stable complex, but it does not contract around acetylcholine, which results in a more dynamic complex. (C) The ability of VU154 to bind to the receptor varies from species to species and is higher in mice compared to humans. However, introducing mutations to make the genetic sequence in the human receptor more like that of the mouse receptor led to an increase in binding affinity.

To uncover the molecular basis for these results, Vuckovic et al. used cryogenic electron microscopy (cryoEM) to obtain four structures of M4 AChR bound to its cognate G protein and in complex with various ligands. The structural analyses – combined with molecular dynamics simulations – enabled the authors to uncover the underlying dynamics and conformational changes that are otherwise missed through static snapshots of cryoEM structures.

The experiments revealed that the allosteric sites for both VU154 and LY298 were, as expected, located in a region of the receptor called the extracellular vestibule. The orthosteric sites overlapped with those in other members of the mAChR subfamily and were located inside a central ‘pocket’ in the receptor; However, it was noticed that this pocket was contracted around iperoxo but not around acetylcholine. The smaller binding pocket, along with the rotation of a specific tyrosine residue, resulted in more stable interactions for iperoxo within the orthosteric site. On the other hand, the binding of acetylcholine was seen to be more dynamic with fewer stable interactions (Figure 1B).

Surprisingly, even though iperoxo bound to the receptor more tightly than acetylcholine, its ability to promote signaling through the receptor was lower. Vuckovic et al. suggest that since the acetylcholine-bound M4 AChR is more dynamic, it can sample a large range of conformations, including those that couple to and activate G protein. This allows the receptor to efficiently activate the G protein and increase the signaling response.

The structures and molecular dynamics simulations also helped uncover the molecular basis for the probe dependence of the allosteric modulators. It is possible that both had stronger effects on the acetylcholine-bound receptor due to the stabilization of an inherently dynamic structure. Conversely, since the iperoxo-bound receptor was already very stable, the modulatory effects were negligible. This result provides a key future consideration for the development of allosteric drugs that target G protein-coupled receptors.

Using mutational studies, Vuckovic et al. also identified a network of amino acids that were important to the conformational dynamics of the protein, some of which showed maximum variability between structures and modulated the signaling efficacy of both orthosteric and allosteric ligands.

Lastly, the researchers investigated why VU154 is potent in some species but not in others. Based on their initial findings, VU154 was a weaker positive allosteric modulator than LY298 in humans because it poorly stabilized the active receptor conformation. However, its effects in mice were stronger, and were comparable to the effects of LY298 in humans. Using mutational studies, Vuckovic et al. identified three important residues on the human receptor that confer species-selectivity. Mutating these to the equivalent residues in the mouse sequence resulted in improved allostery by VU154 in functional studies and stable binding in simulations.

In conclusion, Vuckovic et al. have described the complex interplay between structure, conformational dynamics and pharmacology that defines allostery at G protein-coupled receptors. Their work provides a detailed framework to guide future drug discovery efforts focused on the muscarinic receptor subfamily.

References

Article and author information

Author details

  1. Saif Khan

    Saif Khan is in the Bridge Institute, USC Michelson Center for Convergent Biosciences, Department of Biological Sciences, University of Southern California, Los Angeles, United States

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3604-2670
  2. Cornelius Gati

    Cornelius Gati is in the Bridge Institute, USC Michelson Center for Convergent Biosciences, Department of Biological Sciences, University of Southern California, Los Angeles, United States

    For correspondence
    gati@usc.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3693-7009

Publication history

  1. Version of Record published: June 2, 2023 (version 1)

Copyright

© 2023, Khan and Gati

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 808
    views
  • 92
    downloads
  • 1
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Saif Khan
  2. Cornelius Gati
(2023)
Drug Discovery: Decoding the mechanisms of allostery
eLife 12:e88749.
https://doi.org/10.7554/eLife.88749

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Roberto Efraín Díaz, Andrew K Ecker ... James S Fraser
    Research Article

    Chitin is an abundant biopolymer and pathogen-associated molecular pattern that stimulates a host innate immune response. Mammals express chitin-binding and chitin-degrading proteins to remove chitin from the body. One of these proteins, Acidic Mammalian Chitinase (AMCase), is an enzyme known for its ability to function under acidic conditions in the stomach but is also active in tissues with more neutral pHs, such as the lung. Here, we used a combination of biochemical, structural, and computational modeling approaches to examine how the mouse homolog (mAMCase) can act in both acidic and neutral environments. We measured kinetic properties of mAMCase activity across a broad pH range, quantifying its unusual dual activity optima at pH 2 and 7. We also solved high-resolution crystal structures of mAMCase in complex with oligomeric GlcNAcn, the building block of chitin, where we identified extensive conformational ligand heterogeneity. Leveraging these data, we conducted molecular dynamics simulations that suggest how a key catalytic residue could be protonated via distinct mechanisms in each of the two environmental pH ranges. These results integrate structural, biochemical, and computational approaches to deliver a more complete understanding of the catalytic mechanism governing mAMCase activity at different pH. Engineering proteins with tunable pH optima may provide new opportunities to develop improved enzyme variants, including AMCase, for therapeutic purposes in chitin degradation.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Marian Brenner, Christoph Zink ... Antje Gohla
    Research Article

    Vitamin B6 deficiency has been linked to cognitive impairment in human brain disorders for decades. Still, the molecular mechanisms linking vitamin B6 to these pathologies remain poorly understood, and whether vitamin B6 supplementation improves cognition is unclear as well. Pyridoxal 5’-phosphate phosphatase (PDXP), an enzyme that controls levels of pyridoxal 5’-phosphate (PLP), the co-enzymatically active form of vitamin B6, may represent an alternative therapeutic entry point into vitamin B6-associated pathologies. However, pharmacological PDXP inhibitors to test this concept are lacking. We now identify a PDXP and age-dependent decline of PLP levels in the murine hippocampus that provides a rationale for the development of PDXP inhibitors. Using a combination of small-molecule screening, protein crystallography, and biolayer interferometry, we discover, visualize, and analyze 7,8-dihydroxyflavone (7,8-DHF) as a direct and potent PDXP inhibitor. 7,8-DHF binds and reversibly inhibits PDXP with low micromolar affinity and sub-micromolar potency. In mouse hippocampal neurons, 7,8-DHF increases PLP in a PDXP-dependent manner. These findings validate PDXP as a druggable target. Of note, 7,8-DHF is a well-studied molecule in brain disorder models, although its mechanism of action is actively debated. Our discovery of 7,8-DHF as a PDXP inhibitor offers novel mechanistic insights into the controversy surrounding 7,8-DHF-mediated effects in the brain.